1
|
Karnatak R, Sandkovsky U. Risk of Infections With Long-Term Left Ventricular Assist Device Support. Cureus 2023; 15:e41412. [PMID: 37546149 PMCID: PMC10402930 DOI: 10.7759/cureus.41412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/05/2023] [Indexed: 08/08/2023] Open
Abstract
The average life expectancy post-left ventricular assist device (LVAD) implantation has significantly increased in recent years. Impaired cellular immunity post-LVAD implantation has been suggested. It is not clear if a prolonged duration of LVAD support will lead to an increase in infections and possibly cause opportunistic infections, as seen in immunocompromised patients. METHODS We retrospectively reviewed all the patients who underwent new continuous-flow (C-F) LVAD implantation between January 1, 2013, and December 31, 2014, at the University of Nebraska Medical Center. Patients were followed until heart transplant, LVAD explantation, death, or December 31, 2017. We defined LVAD infections as per the International Society of Heart and Lung Transplantation (ISHLT) definition: VAD-specific, VAD-related, and non-VAD infections. The primary outcome was to calculate the incidence of LVAD infections per 1000 days of LVAD support. Secondary outcomes were to assess the cause of death and the effect of bloodstream infections on LVAD thrombosis, stroke, and death. RESULTS During the study period, a total of 94 patients underwent a C-F LVAD implantation. Five patients were lost in follow-up; 89 patients were included in the study. The mean age at LVAD implantation was 54 (SD+15) years. Out of 89 patients, 67 (75%) were men, and 53/89 (71%) received LVAD as destination therapy (DT). At the time of LVAD implantation, 34/89 (38%) patients had ITERMACS (interagency registry for mechanically assisted circulatory support) score 1 (cardiogenic shock). The median duration of LVAD support was 387+493 days, with an interquartile range of 140 to 1083 days. The incidence rate of infections post-LVAD implantation decreased from 3.2 /1000 LVAD days (95% confidence interval [CI] 2.54-4.03) during the first year of LVAD support to 0.78/1000 LVAD days (95% CI, 0.38-1.65) during the following third year of LVAD support. Similarly, the incidence of VAD-specific infections in the first year post-LVAD implantation versus the third-year post LVAD implantation decreased from 0.83/1000 LVAD days (95% CI, 0.53-1.30) to 0.33/1000 LVAD days (95% CI, 0.10-1.04). On univariate survival analysis, an increased risk of death was associated with a one-year increase in age at LVAD implantation (hazard ratio (HR) 1.05 (95% CI, 1.01-1.09), p=0.01), the presence of infection within 30 days before LVAD implantation (HR 2.44 (95% CI, 1.09-5.48), p=0.03), underlying ischemic cardiomyopathy (HR 2.96 (95% CI, 1.28-6.80), p=0.01), and lower ITERMACS profile HR 3.64 (95% CI, 1.09-12.13, p=0.04). Bloodstream infections (BSIs) were not associated with an increased risk of death (HR 1.63 (95% CI, 0.56-4.80, p=0.37). Univariate survival analysis for poor outcomes (LVAD thrombosis, stroke, or death) showed BSIs increased the risk of having a poor outcome (HR 2.39 (95% CI, 1.02-5.57), p=0.04). CONCLUSIONS The incidence rate of post-LVAD infections decreased significantly over time. LVAD implantation may not be contributing to immune suppression as previously suggested. In our study, BSIs were found to have a significantly increased hazard ratio for a poor outcome post-LVAD implantation.
Collapse
Affiliation(s)
- Rajendra Karnatak
- Infectious Disease and Critical Care Medicine, Aurora Health, Milwaukee, USA
| | - Uriel Sandkovsky
- Division of Infectious Disease, Baylor University Medical Center, Dallas, USA
| |
Collapse
|
2
|
Belfort DDSP, Biselli B, Ávila MS, Lira MTSDS, Galas FRBG, Steffen SP, Gaiotto FA, Jatene FB, Bocchi EA, Ferreira SMA. COVID-19 complicating perioperative management of LVAD implantation: A case report and systematic review. J Card Surg 2021; 36:3405-3409. [PMID: 34091934 PMCID: PMC8242914 DOI: 10.1111/jocs.15690] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 05/14/2021] [Accepted: 05/23/2021] [Indexed: 01/05/2023]
Abstract
The coronavirus 2019 disease (COVID-19) affected 125 million people worldwide and caused 2.7 million deaths. Some comorbidities are associated with worse prognosis and left ventricular assist device (LVAD) recipients are probably part of this high-risk population. We report a 31-year-old male patient who developed COVID-19 during LVAD implantation. His postoperative period was complicated by severe pneumonia and mechanical ventilation (MV) leading to right ventricular failure (RVF) and inotrope necessity. He experienced multiple complications, but eventually recovered. We present a systematic review of LVAD recipients and COVID-19. Among 14 patients, the mean age was 62.7 years, 78.5% were male. A total of 5 patients (35.7%) required MV and 3 patients (21.4%) died. A total of 2 patients (14.2%) had thromboembolic events. This case and systematic review suggest LVAD recipients are at particular risk of unfavorable outcomes and they may be more susceptible to RVF in the setting of COVID-19, particularly during perioperative period.
Collapse
Affiliation(s)
- Deborah de Sá Pereira Belfort
- Department of Heart Failure, Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Bruno Biselli
- Department of Heart Failure, Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Mônica Samuel Ávila
- Department of Heart Failure, Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Maria Tereza Sampaio de Sousa Lira
- Department of Heart Failure, Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Filomena Regina Barbosa Gomes Galas
- Department of Heart Failure, Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Samuel Padovani Steffen
- Department of Heart Failure, Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Fabio Antonio Gaiotto
- Department of Heart Failure, Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Fabio Biscegli Jatene
- Department of Heart Failure, Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Edimar Alcides Bocchi
- Department of Heart Failure, Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| | - Silvia Moreira Ayub Ferreira
- Department of Heart Failure, Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de MedicinaUniversidade de São PauloSão PauloBrazil
| |
Collapse
|
3
|
Choi AY, Manook M, Olaso D, Ezekian B, Park J, Freischlag K, Jackson A, Knechtle S, Kwun J. Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. Front Immunol 2021; 12:694763. [PMID: 34177960 PMCID: PMC8226120 DOI: 10.3389/fimmu.2021.694763] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Accepted: 05/24/2021] [Indexed: 01/11/2023] Open
Abstract
There is an urgent need for therapeutic interventions for desensitization and antibody-mediated rejection (AMR) in sensitized patients with preformed or de novo donor-specific HLA antibodies (DSA). The risk of AMR and allograft loss in sensitized patients is increased due to preformed DSA detected at time of transplant or the reactivation of HLA memory after transplantation, causing acute and chronic AMR. Alternatively, de novo DSA that develops post-transplant due to inadequate immunosuppression and again may lead to acute and chronic AMR or even allograft loss. Circulating antibody, the final product of the humoral immune response, has been the primary target of desensitization and AMR treatment. However, in many cases these protocols fail to achieve efficient removal of all DSA and long-term outcomes of patients with persistent DSA are far worse when compared to non-sensitized patients. We believe that targeting multiple components of humoral immunity will lead to improved outcomes for such patients. In this review, we will briefly discuss conventional desensitization methods targeting antibody or B cell removal and then present a mechanistically designed desensitization regimen targeting plasma cells and the humoral response.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Stuart Knechtle
- Duke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC, United States
| | - Jean Kwun
- Duke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC, United States
| |
Collapse
|
4
|
Early sST2 Liberation after Implantation of a Left Ventricular Assist Device in Patients with Advanced Heart Failure. J Immunol Res 2020; 2020:5826176. [PMID: 36301686 PMCID: PMC7781699 DOI: 10.1155/2020/5826176] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2020] [Revised: 11/24/2020] [Accepted: 12/05/2020] [Indexed: 11/18/2022] Open
Abstract
Background The use of left ventricular assist device (LVAD) has increased considerably over the past decade; however, there is limited literature to assist in patient selection and monitoring. The frequency of adverse events remains high. We examined the early expression of circulating soluble ST2 (sST2), a biomarker with immunosuppressive and profibrotic activity, and assessed the risk of death at 1 year in patients receiving LVAD implant. Methods We prospectively enrolled 20 heart failure patients and measured sST2, IL-33, and IL-6 serum concentrations over three weeks after LVAD implantation. We compared the kinetics of IL-6, sST2, and IL-33 release in survivors with those of nonsurvivors using mixed model two-way analysis of variance for repeated measures. We also collected data on hemodynamic parameters (i.e., cardiac output) and frequency of infections during the hospital stay. Results LVAD therapy led to an immediate and significant improvement of the hemodynamic parameters in 1-year survivors and nonsurvivors alike. The 1-year survival rate was 65%. IL-6 concentrations showed a significant (p = 0.03) peak at admission to the intensive care unit following LVAD implantation, whereas sST2 levels were massively increased (p < 0.0003) on day 1. While 1-year survivors had persistently lower sST2 values compared to nonsurvivors during the first 3 weeks after LVAD implantation (p = 0.012), no differences were observed in the temporal pattern of IL-6 or IL-33. The odds of detecting Candida species in the bronchoalveolar lavage fluid were 14 times higher in nonsurvivors than in survivors (OR 13.7, CI 1.4-127, p = 0.02). Conclusion In patients implanted with LVAD, circulating sST2 levels and frequency of Candida colonisation were associated with higher mortality. Awareness of this early immune response can guide physicians in risk-benefit analysis.
Collapse
|
5
|
Cyriaque V, Géron A, Billon G, Nesme J, Werner J, Gillan DC, Sørensen SJ, Wattiez R. Metal-induced bacterial interactions promote diversity in river-sediment microbiomes. FEMS Microbiol Ecol 2020; 96:5826176. [PMID: 32343356 DOI: 10.1093/femsec/fiaa076] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Accepted: 04/27/2020] [Indexed: 01/05/2023] Open
Abstract
Anthropogenic metal contamination results in long-term environmental selective pressure with unclear impacts on bacterial communities, which comprise key players in ecosystem functioning. Since metal contamination poses serious toxicity and bioaccumulation issues, assessing their impact on environmental microbiomes is important to respond to current environmental and health issues. Despite elevated metal concentrations, the river sedimentary microbiome near the MetalEurop foundry (France) shows unexpected higher diversity compared with the upstream control site. In this work, a follow-up of the microbial community assembly during a metal contamination event was performed in microcosms with periodic renewal of the supernatant river water. Sediments of the control site were gradually exposed to a mixture of metals (Cd, Cu, Pb and Zn) in order to reach similar concentrations to MetalEurop sediments. Illumina sequencing of 16S rRNA gene amplicons was performed. Metal-resistant genes, czcA and pbrA, as well as IncP plasmid content, were assessed by quantitative PCR. The outcomes of this study support previous in situ observations showing that metals act as community assembly managers, increasing diversity. This work revealed progressive adaptation of the sediment microbiome through the selection of different metal-resistant mechanisms and cross-species interactions involving public good-providing bacteria co-occurring with the rest of the community.
Collapse
Affiliation(s)
- Valentine Cyriaque
- Proteomics and Microbiology Laboratory, Research Institute for Biosciences, UMONS, 20 Place du Parc, 7000 Mons, Belgium
| | - Augustin Géron
- Proteomics and Microbiology Laboratory, Research Institute for Biosciences, UMONS, 20 Place du Parc, 7000 Mons, Belgium.,Division of Biological and Environmental Sciences, Faculty of Natural Sciences, University of Stirling, Stirling,FK9 4LA, UK
| | - Gabriel Billon
- Univ. Lille, CNRS, UMR 8516 - LASIRE - LAboratoire de Spectroscopie pour les Interactions, la Réactivité et l'Environnement, F-59000 Lille, France
| | - Joseph Nesme
- Section of Microbiology, Department of Biology, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Johannes Werner
- Department of Biological Oceanography, Leibniz Institute of Baltic Sea Research, D-18119 Rostock, Germany
| | - David C Gillan
- Proteomics and Microbiology Laboratory, Research Institute for Biosciences, UMONS, 20 Place du Parc, 7000 Mons, Belgium
| | - Søren J Sørensen
- Section of Microbiology, Department of Biology, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Ruddy Wattiez
- Proteomics and Microbiology Laboratory, Research Institute for Biosciences, UMONS, 20 Place du Parc, 7000 Mons, Belgium
| |
Collapse
|
6
|
Characteristics and Outcomes of Patients With a Left Ventricular Assist Device With Coronavirus Disease-19. J Card Fail 2020; 26:895-897. [PMID: 32956813 PMCID: PMC7501531 DOI: 10.1016/j.cardfail.2020.09.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 08/31/2020] [Accepted: 09/14/2020] [Indexed: 12/15/2022]
|
7
|
In Vitro Benchmarking Study of Ventricular Assist Devices in Current Clinical Use. J Card Fail 2020; 26:70-79. [DOI: 10.1016/j.cardfail.2019.09.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Revised: 09/24/2019] [Accepted: 09/28/2019] [Indexed: 01/26/2023]
|
8
|
Wrobel CA, Drazner MH, Ayers CR, Pham DD, La Hoz RM, Grodin JL, Garg S, Mammen PPA, Morlend RM, Araj F, Amin AA, Cornwell WK, Thibodeau JT. Delayed febrile response with bloodstream infections in patients with continuous-flow left ventricular assist devices. J Investig Med 2019; 67:653-658. [PMID: 30696751 DOI: 10.1136/jim-2018-000893] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/28/2018] [Indexed: 11/03/2022]
Abstract
Bloodstream infections (BSIs) are common in patients with continuous-flow left ventricular assist devices (CF-LVADs). Whether CF-LVADs modulate the febrile response to BSIs is unknown. We retrospectively compared the febrile response to BSIs in patients with heart failure (HF) with CF-LVADs versus a control population of patients with HF receiving inotropic infusions. BSIs were adjudicated using the Centers for Disease Control and Prevention and the National Healthcare Safety Network criteria. Febrile status (temperature ≥38°C, 100.4 °F), temperature at presentation with BSI, and the highest temperature within 72 hours (Tmax) were collected. We observed 59 BSIs in LVAD patients and 45 BSIs in controls. LVAD patients were more likely to be afebrile and to have a lower temperature at presentation than control (88% vs 58%, p=0.002, and 37°C ±0.7 vs 37.7°C ±1.0, p=0.0009, respectively). By 72 hours, the difference in afebrile status diminished (53% vs 44%, p=0.42), and the Tmax was similar between the LVAD and control groups (37.9°C±0.9 vs 38.2°C±0.8, respectively, p=0.10). In conclusion, at presentation with a BSI, the vast majority of CF-LVAD patients were afebrile, an event which occurred at a higher frequency when compared with patients with advanced HF on chronic inotropes via an indwelling venous catheter. These data alert clinicians to have a very low threshold to obtain blood cultures in CF-LVAD patients even in the absence of fever. Further study is needed to determine whether a delayed or diminished febrile response represents another pathophysiological consequence of CF-LVADs.
Collapse
Affiliation(s)
- Christopher A Wrobel
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Mark H Drazner
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Colby R Ayers
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - David D Pham
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Ricardo M La Hoz
- Department of Internal Medicine, Division of Infectious Disease, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Justin L Grodin
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Sonia Garg
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Pradeep P A Mammen
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Robert M Morlend
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Faris Araj
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Alpesh A Amin
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - William K Cornwell
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Jennifer T Thibodeau
- Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| |
Collapse
|
9
|
Radley G, Ali S, Pieper IL, Thornton CA. Mechanical shear stress and leukocyte phenotype and function: Implications for ventricular assist device development and use. Int J Artif Organs 2018; 42:133-142. [PMID: 30585115 DOI: 10.1177/0391398818817326] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Heart failure remains a disease of ever increasing prevalence in the modern world. Patients with end-stage heart failure are being referred increasingly for mechanical circulatory support. Mechanical circulatory support can assist patients who are ineligible for transplant and stabilise eligible patients prior to transplantation. It is also used during cardiopulmonary bypass surgery to maintain circulation while operating on the heart. While mechanical circulatory support can stabilise heart failure and improve quality of life, complications such as infection and thrombosis remain a common risk. Leukocytes can contribute to both of these complications. Contact with foreign surfaces and the introduction of artificial mechanical shear stress can lead to the activation of leukocytes, reduced functionality and the release of pro-inflammatory and pro-thrombogenic microparticles. Assessing the impact of mechanical trauma to leukocytes is largely overlooked in comparison to red blood cells and platelets. This review provides an overview of the available literature on the effects of mechanical circulatory support systems on leukocyte phenotype and function. One purpose of this review is to emphasise the importance of studying mechanical trauma to leukocytes to better understand the occurrence of adverse events during mechanical circulatory support.
Collapse
Affiliation(s)
- Gemma Radley
- Swansea University Medical School, Swansea, UK
- Calon Cardio-Technology Ltd, Institute of Life Science, Swansea, UK
| | - Sabrina Ali
- Calon Cardio-Technology Ltd, Institute of Life Science, Swansea, UK
| | - Ina Laura Pieper
- Swansea University Medical School, Swansea, UK
- Scandinavian Real Heart AB, Västerås, Sweden
| | | |
Collapse
|
10
|
Radley G, Pieper IL, Ali S, Bhatti F, Thornton CA. The Inflammatory Response to Ventricular Assist Devices. Front Immunol 2018; 9:2651. [PMID: 30498496 PMCID: PMC6249332 DOI: 10.3389/fimmu.2018.02651] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Accepted: 10/26/2018] [Indexed: 12/27/2022] Open
Abstract
The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients who are ineligible for transplant has increased steadily in the last decade. In parallel, improvements in VAD design have reduced device size, cost, and device-related complications. These complications include infection and thrombosis which share underpinning contribution from the inflammatory response and remain common risks from VAD implantation. An added and underappreciated difficulty in designing a VAD that supports heart function and aids the repair of damaged myocardium is that different types of HF are accompanied by different inflammatory profiles that can affect the response to the implanted device. Circulating inflammatory markers and changes in leukocyte phenotypes receive much attention as biomarkers for mortality and disease progression. However, they are seldom used to monitor progress during and outcomes from VAD therapy or during the design phase for new devices. Even the partial reversal of heart damage associated with heart failure is a desirable outcome from VAD use. Therefore, improved understanding of the interplay between VADs and the recipient's inflammatory response would potentially increase their uptake, improve patient lives, and fuel research related to other blood-contacting medical devices. Here we provide a review of what is currently known about inflammation in heart failure and how this inflammatory profile is altered in heart failure patients receiving VAD therapy.
Collapse
Affiliation(s)
- Gemma Radley
- Swansea University Medical School, Swansea, United Kingdom.,Calon Cardio-Technology Ltd, Institute of Life Science, Swansea, United Kingdom
| | - Ina Laura Pieper
- Swansea University Medical School, Swansea, United Kingdom.,Scandinavian Real Heart AB, Västerås, Sweden
| | - Sabrina Ali
- Calon Cardio-Technology Ltd, Institute of Life Science, Swansea, United Kingdom
| | - Farah Bhatti
- Department of Cardiology, Morriston Hospital, Abertawe Bro Morgannwg University Health Board, Swansea, United Kingdom
| | | |
Collapse
|
11
|
Pieper IL, Radley G, Christen A, Ali S, Bodger O, Thornton CA. Ovine Leukocyte Microparticles Generated by the CentriMag Ventricular Assist Device In Vitro. Artif Organs 2018; 42:E78-E89. [PMID: 29512167 DOI: 10.1111/aor.13068] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2017] [Revised: 10/06/2017] [Accepted: 10/12/2017] [Indexed: 12/13/2022]
Abstract
Ventricular assist devices (VADs) are a life-saving form of mechanical circulatory support in heart failure patients. However, VADs have not yet reached their full potential due to the associated side effects (thrombosis, bleeding, infection) related to the activation and damage of blood cells and proteins caused by mechanical stress and foreign materials. Studies of the effects of VADs on leukocytes are limited, yet leukocyte activation and damage including microparticle generation can influence both thrombosis and infection rates. Therefore, the aim was to develop a multicolor flow cytometry assessment of leukocyte microparticles (LMPs) using ovine blood and the CentriMag VAD as a model for shear stress. Ovine blood was pumped for 6 h in the CentriMag and regular samples analyzed for hemolysis, complete blood counts and LMP by flow cytometry during three different pump operating conditions (low flow, standard, high speed). The high speed condition caused significant increases in plasma-free hemoglobin; decreases in total leukocytes, granulocytes, monocytes, and platelets; increases in CD45+ LMPs as well as two novel LMP populations: CD11bbright /HLA-DR- and CD11bdull /HLA-DR+ , both of which were CD14- /CD21- . CD11bbright /HLA-DR- LMPs appeared to respond to an increase in shear magnitude whereas the CD11bdull /HLA-DR+ LMPs significantly increased in all pumping conditions. We propose that these two populations are released from granulocytes and T cells, respectively, but further research is needed to better characterize these two populations.
Collapse
Affiliation(s)
- Ina Laura Pieper
- Institute of Life Science, Swansea University Medical School, Swansea, UK.,Calon Cardio-Technology Ltd, Institute of Life Science, Swansea, UK
| | - Gemma Radley
- Institute of Life Science, Swansea University Medical School, Swansea, UK.,Calon Cardio-Technology Ltd, Institute of Life Science, Swansea, UK
| | - Abigail Christen
- Calon Cardio-Technology Ltd, Institute of Life Science, Swansea, UK
| | - Sabrina Ali
- Calon Cardio-Technology Ltd, Institute of Life Science, Swansea, UK
| | - Owen Bodger
- Institute of Life Science, Swansea University Medical School, Swansea, UK
| | | |
Collapse
|
12
|
Pieper IL, Radley G, Chan CHH, Friedmann Y, Foster G, Thornton CA. Quantification methods for human and large animal leukocytes using DNA dyes by flow cytometry. Cytometry A 2016; 89:565-74. [DOI: 10.1002/cyto.a.22874] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Revised: 02/19/2016] [Accepted: 04/26/2016] [Indexed: 01/18/2023]
Affiliation(s)
- Ina Laura Pieper
- Institute of Life Science, Swansea University Medical School; Swansea SA2 8PP United Kingdom
- Calon Cardio-Technology, Institute of Life Science; Swansea SA2 8PP United Kingdom
| | - Gemma Radley
- Institute of Life Science, Swansea University Medical School; Swansea SA2 8PP United Kingdom
- Calon Cardio-Technology, Institute of Life Science; Swansea SA2 8PP United Kingdom
| | - Chris H. H. Chan
- Institute of Life Science, Swansea University Medical School; Swansea SA2 8PP United Kingdom
- Calon Cardio-Technology, Institute of Life Science; Swansea SA2 8PP United Kingdom
| | - Yasmin Friedmann
- Institute of Life Science, Swansea University Medical School; Swansea SA2 8PP United Kingdom
| | - Graham Foster
- Calon Cardio-Technology, Institute of Life Science; Swansea SA2 8PP United Kingdom
| | - Catherine A. Thornton
- Institute of Life Science, Swansea University Medical School; Swansea SA2 8PP United Kingdom
| |
Collapse
|
13
|
Chan CHH, Pieper IL, Hambly R, Radley G, Jones A, Friedmann Y, Hawkins KM, Westaby S, Foster G, Thornton CA. The CentriMag centrifugal blood pump as a benchmark for in vitro testing of hemocompatibility in implantable ventricular assist devices. Artif Organs 2015; 39:93-101. [PMID: 25066768 PMCID: PMC4338790 DOI: 10.1111/aor.12351] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Implantable ventricular assist devices (VADs) have proven efficient in advanced heart failure patients as a bridge-to-transplant or destination therapy. However, VAD usage often leads to infection, bleeding, and thrombosis, side effects attributable to the damage to blood cells and plasma proteins. Measuring hemolysis alone does not provide sufficient information to understand total blood damage, and research exploring the impact of currently available pumps on a wider range of blood cell types and plasma proteins such as von Willebrand factor (vWF) is required to further our understanding of safer pump design. The extracorporeal CentriMag (Thoratec Corporation, Pleasanton, CA, USA) has a hemolysis profile within published standards of normalized index of hemolysis levels of less than 0.01 g/100 L at 100 mm Hg but the effect on leukocytes, vWF multimers, and platelets is unknown. Here, the CentriMag was tested using bovine blood (n = 15) under constant hemodynamic conditions in comparison with a static control for total blood cell counts, hemolysis, leukocyte death, vWF multimers, microparticles, platelet activation, and apoptosis. The CentriMag decreased the levels of healthy leukocytes (P < 0.006), induced leukocyte microparticles (P < 10(-5) ), and the level of high molecular weight of vWF multimers was significantly reduced in the CentriMag (P < 10(-5) ) all compared with the static treatment after 6 h in vitro testing. Despite the leukocyte damage, microparticle formation, and cleavage of vWF multimers, these results show that the CentriMag is a hemocompatible pump which could be used as a standard in blood damage assays to inform the design of new implantable blood pumps.
Collapse
Affiliation(s)
- Chris H H Chan
- Institute of Life Science, College of Medicine, Swansea University, Swansea, Wales, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Beydoun K, Wenzel R. Left Ventricular Assist Device Endocarditis Caused by Vancomycin-Intermediate Staphylococcus aureus Successfully Treated with Ceftaroline: a Review of the Clinical Case and Overview of Vancomycin Resistance in Staphylococcus aureus. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/j.clinmicnews.2013.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Mitchell A, Guan W, Staggs R, Hamel A, Hozayen S, Adhikari N, Grindle S, Desir S, John R, Hall JL, Eckman P. Identification of differentially expressed transcripts and pathways in blood one week and six months following implant of left ventricular assist devices. PLoS One 2013; 8:e77951. [PMID: 24205042 PMCID: PMC3804545 DOI: 10.1371/journal.pone.0077951] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Accepted: 09/06/2013] [Indexed: 11/19/2022] Open
Abstract
Introduction Continuous-flow left ventricular assist devices (LVADs) are an established therapy for patients with end-stage heart failure. The short- and long-term impact of these devices on peripheral blood gene expression has not been characterized, and may provide insight into the molecular pathways mediated in response to left ventricular remodeling and an improvement in overall systemic circulation. We performed RNA sequencing to identify genes and pathways influenced by these devices. Methods RNA was extracted from blood of 9 heart failure patients (8 male) prior to LVAD implantation, and at 7 and 180 days postoperatively. Libraries were sequenced on an Illumina HiSeq2000 and sequences mapped to the human Ensembl GRCh37.67 genome assembly. Results A specific set of genes involved in regulating cellular immune response, antigen presentation, and T cell activation and survival were down-regulated 7 days after LVAD placement. 6 months following LVAD placement, the expression levels of these genes were significantly increased; yet importantly, remained significantly lower than age and sex-matched samples from healthy controls. Conclusions In summary, this genomic analysis identified a significant decrease in the expression of genes that promote a healthy immune response in patients with heart failure that was partially restored 6 months following LVAD implant.
Collapse
Affiliation(s)
- Adam Mitchell
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Weihua Guan
- Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Rodney Staggs
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Aimee Hamel
- Lillehei Clinical Research Unit, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Sameh Hozayen
- Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Neeta Adhikari
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Suzanne Grindle
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Snider Desir
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Ranjit John
- Department of Surgery, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Jennifer L. Hall
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- * E-mail: (JH); (PE)
| | - Peter Eckman
- Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
- * E-mail: (JH); (PE)
| |
Collapse
|
16
|
Cannon A, Elliott T, Ballew C, Cavey J, O'Shea G, Franzwa J, Puhlman M, Bennett J, Ryan T, Lockard K, Avrahami N, Brennan P, Kurien S, Andrus S, Dick S, Davis E. Variability in infection control measures for the percutaneous lead among programs implanting long-term ventricular assist devices in the United States. Prog Transplant 2013. [PMID: 23187051 DOI: 10.7182/pit2012612] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Ventricular assist devices (VADs) are a surgical treatment for heart failure. These devices may be implanted as a bridge to transplant or as destination therapy. After surgical recovery and education regarding device care, patients are discharged home. Meticulous care of the driveline must be taken to prevent infection and trauma of the site throughout the perioperative event and for the duration of support. Currently a standardized protocol for care of the driveline and exit site does not exist. VAD coordinators from across the country discussed the variability in care at different centers in the United States through a series of conference calls. A survey consisting of 16 questions was developed. The survey included questions on preoperative antibiotic recommendations, driveline placement and exit site suturing, frequency of dressing changes, and showering practices. VAD coordinators shared center-specific dressing protocols and any driveline success stories. This survey was sent to 73 centers; 38 centers (52%) responded. The purpose of the survey was to define current practice in order to move toward a standard of practice or protocol based on expert opinion for VAD driveline care and to assess the need for future studies.
Collapse
Affiliation(s)
- Anne Cannon
- University of Colorado Hospital, Aurora, CO, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Maniar S, Kondareddy S, Topkara VK. Left ventricular assist device-related infections: past, present and future. Expert Rev Med Devices 2012; 8:627-34. [PMID: 22026627 DOI: 10.1586/erd.11.36] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Over the last decade, left ventricular assist device (LVAD) implantation has emerged as an alternative treatment strategy in patients with advanced heart failure irrespective of their transplant eligibility. However, success and applicability of this therapy is largely limited by high complication rates associated with these devices. Although superior outcomes have been achieved with the second-generation continuous-flow LVADs, device-related infections continue to be a prevalent complication in this patient population and contribute significantly to the financial burden of this therapy due to an increased need for hospitalizations and surgical interventions. Patient selection, device design and LVAD-induced immune system dysfunction appear to be major risk factors for the development of device-related infections. Improvements in device design and better patient selection strategies, particularly with respect to identifying individuals with genetic susceptibility to device-related infections, may further reduce this prevalent complication and improve outcomes in patients with advanced heart failure.
Collapse
Affiliation(s)
- Sanjay Maniar
- Center for Cardiovascular Research, Division of Cardiology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus PO Box 8066, St Louis, MO 63110-1093, USA
| | | | | |
Collapse
|
18
|
Abstract
As life expectancy continues to increase and biotechnology advances, the use of cardiovascular implantable devices will continue to rise. Unfortunately, despite modern medical advances, the infection and mortality rates remain excessively elevated. This article reviews the pathophysiology and general concepts of cardiac device-related infections, including the physical and chemical characteristics of the medical device, host response to the medical device, and the microbiologic virulence factors. Infections of the most commonly utilized cardiovascular implantable devices, including cardiovascular implantable electronic devices, bioprosthetic and mechanical valves, ventricular assist devices, total artificial hearts, and coronary artery stents, are reviewed in detail.
Collapse
|
19
|
Ensor CR, Paciullo CA, Cahoon WD, Nolan PE. Pharmacotherapy for Mechanical Circulatory Support: A Comprehensive Review. Ann Pharmacother 2011; 45:60-77. [DOI: 10.1345/aph.1p459] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Objective To provide a comprehensive review of the pharmacotherapy associated with the provision of mechanical circulatory support (MCS) to patients with end-stage heart failure and guidance regarding the selection, assessment, and optimization of drug therapy for this population. Data Sources: The MEDLINE/PubMed, EMBASE, and Cochrane databases were searched from 1960 to July 2010 for articles published in English using the search terms mechanical circulatory support, ventricular assist system, ventricular assist device, left ventricular assist device, right ventricular assist device, biventricular assist device, total artificial heart, pulsatile, positive displacement, axial, centrifugal, hemostasis, bleeding, hemodynamic, blood pressure, thrombosis, antithrombotic therapy, anticoagulant, antiplatelet, right ventricular failure, ventricular arrhythmia, anemia, arteriovenous malformation, stroke, infection, and clinical pharmacist. Study Selection And Data Extraction: All relevant original studies, metaanalyses, systematic reviews, guidelines, and reviews were assessed for inclusion. References from pertinent articles were examined for content not found during the initial search. Data Synthesis: MCS has advanced significantly since the first left ventricular assist device was implanted in 1966. Further advancements in MCS technology that occurred in the tatter decade are changing the overall management of end-stage heart failure care and cardiac transplantation. These pumps allow for improved bridge-to-transplant rates, enhanced survival, and quality of life. Pharmacotherapy associated with MCS devices may optimize the performance of the pumps and improve patient outcomes, as well as minimize morbidity related to their adverse effects. This review highlights the knowledge needed to provide appropriate clinical pharmacy services for patients supported by MCS devices. Conclusions: The HeartMate II clinical investigators called for the involvement of pharmacists in MCS patient assessment and optimization. Pharmacotherapeutic management of patients supported with MCS devices requires individualized care, with pharmacists as part of the team, based on the characteristics of each pump and recipient.
Collapse
Affiliation(s)
- Christopher R Ensor
- Cardiothoracic Transplantation and Mechanical Circulatory Support; Clinical Assistant Professor, School of Pharmacy, University of Maryland; Department of Pharmacy, Comprehensive Transplant Center, The Johns Hopkins Hospital, Baltimore, MD
| | - Christopher A Paciullo
- Cardiothoracic Surgery Critical Care, Department of Pharmacy, Emory University Hospital, Atlanta, GA
| | - William D Cahoon
- Cardiology; Clinical Assistant Professor, School of Pharmacy, Virginia Commonwealth University, Virginia Commonwealth University Health System; Department of Pharmacy, Medical College of Virginia Hospitals, Richmond, VA
| | - Paul E Nolan
- College of Pharmacy, University of Arizona; Senior Clinical Scientist, The University Medical Center, Tucson, AZ
| |
Collapse
|
20
|
Aslam S, Hernandez M, Thornby J, Zeluff B, Darouiche RO. Risk factors and outcomes of fungal ventricular-assist device infections. Clin Infect Dis 2010; 50:664-71. [PMID: 20113174 DOI: 10.1086/650454] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Infection is a common complication of ventricular-assist devices (VADs) and is associated with rehospitalization, thromboembolic events, VAD malfunction, delay in heart transplantation, and a high mortality rate. The objectives of this study were to investigate the frequency of fungal VAD infections and assess various risk factors and their effects on mortality as compared with bacterial VAD infections. METHODS We conducted a retrospective chart review of patients with infected VADs at a single tertiary care center. The frequency, risk factors, and outcomes of fungal versus bacterial VAD infections were compared. RESULTS Of the 300 patients who received a VAD, 108 (36%) developed VAD infection, including 85 bacterial and 23 fungal infections. Most common bacterial causes of infection were Staphylococcus aureus, coagulase-negative staphylococci, enterococci, and Pseudomonas aeuruginosa. The most common fungal etiologic agent was Candida albicans. Only the use of total parenteral nutrition was associated with the development of a fungal VAD infection in multivariate analysis (odds ratio, 6.95; 95% confidence interval, 1.71-28.16; P=.007). Patients who experienced fungal VAD infection were less likely to be cured (17.4% vs 56.3%; P=.001) and had greater mortality (91% vs 61%; P=.006), compared with those who experienced bacterial VAD infection. CONCLUSIONS Fungi were responsible for approximately one-fifth of VAD infections and were associated with a mortality rate of 91%. Restriction of total parenteral nutrition use is essential in decreasing the rate of fungal VAD infection. Trials are needed for investigating the use of echinocandins or lipid formulations of amphotericin B for prevention and/or treatment of fungal VAD infection.
Collapse
Affiliation(s)
- Saima Aslam
- Baylor College of Medicine, Houston, Texas, USA.
| | | | | | | | | |
Collapse
|
21
|
Wilson SR, Givertz MM, Stewart GC, Mudge GH. Ventricular Assist Devices. J Am Coll Cardiol 2009; 54:1647-59. [DOI: 10.1016/j.jacc.2009.06.035] [Citation(s) in RCA: 119] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2009] [Revised: 06/18/2009] [Accepted: 06/21/2009] [Indexed: 11/15/2022]
|
22
|
Coppage M, Baker M, Fialkow L, Meehan D, Gettings K, Chen L, Massey HT, Blumberg N. Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products. Hum Immunol 2009; 70:413-6. [PMID: 19275923 DOI: 10.1016/j.humimm.2009.03.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2008] [Revised: 02/10/2009] [Accepted: 03/02/2009] [Indexed: 11/17/2022]
Abstract
Ventricular assist devices provide support for a failing heart and often serve as a bridge to transplantation. The use of these devices has also been associated with allosensitization to HLA antigens because of transfusion of blood products. Our program established a protocol mandating the use of leukoreduced, irradiated and ABO identical products, including platelets, in patients receiving initial implantations of VADs as a bridge to transplantation. Recipients were tested for anti-HLA antibodies before VAD implantation and monthly post-implantation by cytotoxicity and solid phase assays. We observed minimal de novo anti-HLA sensitization (<10%) in this population of 55 patients, each receiving a mean of 90 blood components, using this approach. No patient developed broad sensitization (PRA>50%). In conclusion, The use of leukoreduced, irradiated, ABO identical blood products abrogates broad allosensitization in this highly transfused population.
Collapse
Affiliation(s)
- Myra Coppage
- Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Strong Memorial Hospital, Rochester, NY, USA.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Malliaras KG, Terrovitis JV, Drakos SG, Nanas JN. Reverse cardiac remodeling enabled by mechanical unloading of the left ventricle. J Cardiovasc Transl Res 2008; 2:114-25. [PMID: 20559975 DOI: 10.1007/s12265-008-9057-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2008] [Accepted: 09/05/2008] [Indexed: 01/28/2023]
Abstract
Cardiac remodeling is a characteristic and basic component of heart failure progression and is associated with a poor prognosis. Attenuating or reversing remodeling is an accepted goal of heart failure therapy. Cardiac mechanical support with left ventricular assist devices, in addition to its established role as "bridge to transplantation" or "destination therapy" in patients not eligible for cardiac transplantation, offers the potential for significant and sustained myocardial recovery through reverse remodeling. This review discusses the emerging role of left ventricular assist devices as a "bridge to recovery". Clinical and basic aspects of cardiac remodeling and cardiac reverse remodeling enabled by mechanical unloading, potential candidates for this modality of treatment as well as unresolved issues regarding the use of mechanical circulatory support as a bridge to recovery are discussed.
Collapse
|
24
|
Burkhoff D, Klotz S, Mancini DM. LVAD-Induced Reverse Remodeling: Basic and Clinical Implications for Myocardial Recovery. J Card Fail 2006; 12:227-39. [PMID: 16624689 DOI: 10.1016/j.cardfail.2005.10.012] [Citation(s) in RCA: 124] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2005] [Revised: 10/09/2005] [Accepted: 10/18/2005] [Indexed: 10/24/2022]
Abstract
BACKGROUND With improved technology, increasing clinical experience, and expanding indications for use, left ventricular assist devices (LVADs) are assuming a greater role in the care of patients with end-stage heart failure. Early in the course of LVAD use as a bridge to transplant, it became evident that some patients exhibit substantial recovery of ventricular function, which led to the concept of reverse remodeling. METHODS AND RESULTS Herein we summarize and integrate insights derived from a multitude of studies that have investigated how LVAD support influences ventricular structural, cellular, extracellular matrix, molecular, biochemical, and metabolic characteristics of the end-stage failing heart. The focus includes a review of the extent and sustainability of reverse remodeling, the important advances in understanding of the pathophysiology of heart failure derived from these studies and the implications of these findings for development of new therapeutic strategies. CONCLUSION In brief, studies of LVAD-heart interactions have led to the understanding that although we once considered the end-stage failing heart of patients near death to be irreversibly diseased, when given sufficient mechanical unloading and restoration of more normal neurohormonal milieu, a relatively large degree of myocardial recovery is possible. Comparison of effects on right and left ventricles have provided mechanistic insights by implicating hemodynamic unloading as primarily regulating certain aspects of reverse remodeling, neurohormonal factors as regulating other aspects, and joint regulation of still other aspects. As such these observations have driven a shift of thinking of chronic heart failure as a progressive irreversible disease process to a potentially treatable entity.
Collapse
Affiliation(s)
- Daniel Burkhoff
- J. Skirball Center for Cardiovascular Research, Cardiovascular Research Foundation, Orangeburg, NY 10962, USA
| | | | | |
Collapse
|
25
|
Holman WL, Pamboukian SV, Blood M, Tallaj JA, McGiffin DC, Kirklin JK. Managing Device Infections: Are We Progressing or Is Infection an Insurmountable Obstacle? ASAIO J 2005; 51:452-5. [PMID: 16156312 DOI: 10.1097/01.mat.0000169120.48527.87] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
This article reviews infections that occur in patients with implanted mechanical circulatory support devices and presents recent data for signs of progress in controlling the incidence and impact of these infections. Two types of comparisons are used to examine this question. First, the outcomes of patients with HeartMate vented electric left ventricular assist devices (VADs) (Thoratec Corp, Pleasanton, CA) implanted during the REMATCH Trial are compared with the outcome of more recent patients who received this pump as destination therapy. Second, the outcome of patients who received a smaller left VAD (e.g., an axial flow VAD) or a fully implanted left VAD are reported and contrasted with results from the REMATCH era. Data are presented to support the hypothesis that improvements in patient selection, patient management, device durability, and device design have resulted in lower rates of infection and infection-related death for patients who require mechanical circulatory support.
Collapse
Affiliation(s)
- William L Holman
- Department of Surgery, University of Alabama at Birmingham, Birmingham AL, USA
| | | | | | | | | | | |
Collapse
|
26
|
Fitzsimmons CL. Sensitivity, ventricular assist devices, and the waiting game in heart transplantation: what's new? Crit Care Nurs Q 2004; 27:65-77. [PMID: 14974525 DOI: 10.1097/00002727-200401000-00006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Orthotopic heart transplantation became more successful with the introduction of cyclosporine in the late 1970s. Although congestive heart failure has become a significant public health issue and the proportion of patients with advanced heart failure has increased, the number of heart transplants performed has not increased substantially in the past decade. Transplant waiting times have been related to many different factors. Unfortunately, implantation of ventricular assist devices (VADS) may provoke antibody responses. These result in the sensitization of patients and increased waiting time prior to transplantation. The purpose of this article is to explore etiologies of waiting times for pre heart transplant and left ventricular assist device pre heart transplant candidates, explain new theories of sensitization, define current methods to detect sensitization, and discuss nursing care implications.
Collapse
Affiliation(s)
- Catherine L Fitzsimmons
- Department of Cardiology, Heart and Lung Center, University of Texas Southwestern Medical Center, St Paul University Hospital, Dallas, Tex, USA.
| |
Collapse
|
27
|
Birks EJ, Yacoub MH, Banner NR, Khaghani A. The role of bridge to transplantation: should LVAD patients be transplanted? Curr Opin Cardiol 2004; 19:148-53. [PMID: 15075743 DOI: 10.1097/00001573-200403000-00015] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
PURPOSE OF REVIEW The decrease in useable donor organs means an increasing number of patients are requiring support with a left ventricular assist device (LVAD) for survival when their clinical status deteriorates before transplantation. We address whether these patients should be transplanted, if so, with what priority, and when and if they are not transplanted, what are the alternatives? RECENT FINDINGS The perioperative mortality and morbidity of LVAD insertion remains high. Infection and device failure still limit the safety of long periods of bridging and might necessitate earlier transplantation. Early results suggest that the smaller impeller pumps may be associated with a lower incidence of device failure and infection, but with more thromboembolic and hemorrhagic complications. Transplantation of LVAD patients results in survival rates as good as those with conventional transplantation, and the survival benefit is better than for non-LVAD-supported patients. A small number of LVAD patients have shown a significant improvement in myocardial function, sufficient enough to allow explantation of the device. The proportion of these patients has previously been reported to be as low as 5%, but a strategy to maximize recovery has allowed pump removal in approximately two thirds of dilated cardiomyopathy patients. In a recent destination therapy trial, survival in LVAD patients was superior to those on medical therapy, but the frequency of infection, bleeding, and malfunction of the device was higher. SUMMARY LVAD technology is continuing to evolve quickly, while transplantation is here to stay. The interaction between these two powerful modalities requires continued thoughtful evaluation for maximal benefit to patients.
Collapse
Affiliation(s)
- Emma J Birks
- Transplant Unit, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, UK.
| | | | | | | |
Collapse
|
28
|
Ankersmit HJ, Moser B, Hoffman M, Kocher AA, Schlechta B, Boltz-Nitulescu G, Wolner E. Aberrant T-cell activation via CD95 and apoptosis in peripheral T lymphocytes in stable heart transplant recipients. Transplant Proc 2001; 33:2860-1. [PMID: 11498190 DOI: 10.1016/s0041-1345(01)02220-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- H J Ankersmit
- Department of CT Surgery, General Hospital Vienna, Vienna, Austria.
| | | | | | | | | | | | | |
Collapse
|
29
|
Ankersmit HJ, Deicher R, Moser B, Teufel I, Roth G, Gerlitz S, Itescu S, Wolner E, Boltz-Nitulescu G, Kovarik J. Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol 2001; 125:142-8. [PMID: 11472437 PMCID: PMC1906103 DOI: 10.1046/j.1365-2249.2001.01590.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Haemodialysis is a widespread option for end-stage renal disease (ESRD). Long-term success of dialysis is, however, limited by a high rate of serious bacterial and viral infections. We compared T cell functions in ESRD patients undergoing haemodialysis (n = 20), or were not dialysed and received conventional medical treatment (n = 20). Healthy volunteers (n = 15) served as controls. The T cell phenotype was examined by immunofluorescence using fluorochrome-labelled monoclonal antibodies and FACS analysis. The concentration of soluble CD95/Fas and of tumour necrosis factor-alpha receptor type 1 (sTNFR1) in the sera was quantified by ELISA. Activation-induced programmed T cell death was triggered by anti-CD3/CD28 antibodies and measured by 7-AAD staining. All immunological tests were performed at least 1 month after dialysis initiation. T cell proliferation in response to phytohaemagglutinin or anti-CD3 monoclonal antibodies was moderately diminished in non-dialysed patients and markedly reduced in haemodialysis patients compared to healthy controls (P < 0.01 and P < 0.001, respectively). In a mixed lymphocyte culture the proliferative response of T cells from dialysed patients was significantly diminished (P < 0.001). T cells of both non-dialysed and dialysed patients have augmented CD95/Fas and CD45RO expression, increased sCD95/Fas and sTNFR1 release and spontaneously undergo apoptosis. Culture of T cells from haemodialysis patients with anti-CD3/CD28 antibodies increased the proportion of CD4(+) T cells committing activation-induced cell death by a mean 7.5-fold compared to T-helper cells from non-dialysed patients (P < 0.001). Renal failure and initiation of haemodialysis results in a reduced proliferative T cell response, an aberrant state of T cell activation and heightened susceptibility of CD4(+) T cells to activation-induced cell death.
Collapse
Affiliation(s)
- H J Ankersmit
- Department of Surgery, General Hospital of Vienna University, Vienna, Austria.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Tárnok A, Schneider P. Induction of transient immune suppression and Th1/Th2 disbalance by pediatric cardiac surgery with cardiopulmonary bypass. ACTA ACUST UNITED AC 2001. [DOI: 10.1016/s1529-1049(01)00033-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|